Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells

Pharmacological EZH2 inhibition combined with retinoic acid treatment promotes differentiation and apoptosis in rhabdomyosarcoma cells

Abstract Background Rhabdomyosarcomas (RMS) are predominantly paediatric sarcomas thought to originate from muscle precursor cells due to impaired myogenic differentiation. Despite intensive treatment, 5-year survival for patients with advanced disease remains low (< 30%), highlighting a need for...

Full description

Bibliographic Details
Main Authors: Eleanor O’Brien, Carmen Tse, Ian Tracy, Ian Reddin, Joanna Selfe, Jane Gibson, William Tapper, Reuben J. Pengelly, Jinhui Gao, Ewa Aladowicz, Gemma Petts, Khin Thway, Sergey Popov, Anna Kelsey, Timothy J. Underwood, Janet Shipley, Zoë S. Walters
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Clinical Epigenetics
Subjects:
Rhabdomyosarcoma
Differentiation therapy
Epigenetic therapy
EZH2
All-trans retinoic acid
Online Access:https://doi.org/10.1186/s13148-023-01583-w

Internet

https://doi.org/10.1186/s13148-023-01583-w

Similar Items